Objective To study whether there are differences in immunological and hematological indexes in patients with extramed-ullary multiple myeloma(EMM).Methods The medical records of 150 newly diagnosed multiple myeloma(MM)patients admitted to Department of Hematology,the Second Hospital of Lanzhou University from January 2019 to January 2024 were retrospectively analyzed,to compare and analyze the differences in immunological and some hematological indexes between the EMM group(n=60)and the non-EMM group(n=90),and the two subgroups of the different risk stratification DS stages and Mayo myeloma risk stratification.Results The peripheral blood erythrocyte count,hemoglobin level,lactic acid dehydrogenase(LDH)level and interleukins-8(IL-8)levels of the patients in the EMM group were higher than those in the non-EMM group(P＜0.05),the interleukins-10(IL-10)and the pro-portion of CD4+T cells in the EMM group were lower than those in the non-EMM group(P＜0.05).Lymphocyte counts were signifi-cantly higher(P＜0.05)and the proportion of CD8+T cells was significantly lower(P＜0.05)in the EMM group of patients with stand-ard-risk MM.The proportion of peripheral blood CD8+T cells was significantly lower in the EMM group compared with the non-EMM group of patients with high-risk MM(P＜0.05).LDH levels were higher in the EMM group than that in the non-EMM group in both DS-Ⅰ and DS-Ⅱ MM patients(P＜0.05).Peripheral blood erythrocyte count,monocyte count,and hemoglobin level were higher in the EMM group than those in the non-EMM group in DS-Ⅲ MM patients(P＜0.05).Conclusion Immune abnormalities may be one of the factors contributing to the occurrence,development and poor prognosis of EMM.This study suggest that CD8+T cells,as immune effector cells,can be further studied in the occurrence and progression of MM to EMM,providing a new basis for clinical treatment.

Objective:To investigate the clinical and genetic features of a Chinese pedigree with Progressive familial intrahepatic cholestasis (PFIC) and explore its genotype-phenotype correlation.Methods:A patient with PFIC diagnosed at Xinxiang Central Hospital in 2023 was selected as the study subject. The patient was subjected to abdominal magnetic resonance imaging (MRI) and painless gastroscopy. Peripheral blood samples were collected from the patient and his parents for the extraction of genomic DNA and trio-whole exome sequencing (trio-WES). Candidate variants were verified by Sanger sequencing. This study has been approved by the Medical Ethics Committee of Xinxiang Hospital (Ethics No. 2023-241).Results:MRI scan showed that the patient had significantly enlarged liver and spleen. WES revealed that he has harbored compound heterozygous variants of the ATP8B1 gene, including a c. 1710_1711insCCTC (p.A571Pfs*12) frameshifting variant in exon 16 and a c. 2989G>A (p.V997M) missense variant in exon 24, which were respectively inherited from his father and mother, and rated as pathogenic (PVS1+ PM2_Supporting+ PM3+ PP1) and likely pathogenic (PM2_Supporting+ PM3+ PP1) based on the guidelines from the American College of Medical Genetics and Genomics (ACMG). Conclusion:WES can clarify the genetic etiology of patients with speed and accuracy, and facilitate clinical decision-making. The detection of pathogenic variants has provided a basis for clinical diagnosis and enriched the mutational spectrum of the ATP8B1 gene.

The neonatal Fc receptor(FcRn)prolongs the half-life of immunoglobulin G(IgG)and promotes its recycling by binding to and making it an important receptor for maintaining serum IgG homeostasis.However,the abnormal accumulation of pathogenic IgG is closely related to the occurrence of various neuroimmune diseases.FcRn antagonists can significantly reduce the level of pathogenic IgG by blocking the binding of FcRn to IgG,thereby effectively alleviating the clinical symptoms of related diseases.As an emerging targeted therapeutic drug,FcRn antagonists have shown their potential in treating IgG-mediated neuroimmune diseases.This article summarizes the mechanism of action,types and clinical research progress of FcRn antagonists with the aim of providing new ideas for the precise treatment of IgG-mediated neuroimmune diseases.Future research should focus on the long-term safety of drugs,expansion of indications and individualized treatment strategies to further enhance their clinical application value.

OBJECTIVE: To investigate the clinical and genetic features of a Chinese pedigree with Progressive familial intrahepatic cholestasis (PFIC) and explore its genotype-phenotype correlation. METHODS: A patient with PFIC diagnosed at Xinxiang Central Hospital in 2023 was selected as the study subject. The patient was subjected to abdominal magnetic resonance imaging (MRI) and painless gastroscopy. Peripheral blood samples were collected from the patient and his parents for the extraction of genomic DNA and trio-whole exome sequencing (trio-WES). Candidate variants were verified by Sanger sequencing. This study has been approved by the Medical Ethics Committee of Xinxiang Hospital (Ethics No. 2023-241). RESULTS: MRI scan showed that the patient had significantly enlarged liver and spleen. WES revealed that he has harbored compound heterozygous variants of the ATP8B1 gene, including a c.1710_1711insCCTC (p.A571Pfs*12) frameshifting variant in exon 16 and a c.2989G>A (p.V997M) missense variant in exon 24, which were respectively inherited from his father and mother, and rated as pathogenic (PVS1+PM2_Supporting+PM3+PP1) and likely pathogenic (PM2_Supporting+PM3+PP1) based on the guidelines from the American College of Medical Genetics and Genomics (ACMG). CONCLUSION WES can clarify the genetic etiology of patients with speed and accuracy, and facilitate clinical decision-making. The detection of pathogenic variants has provided a basis for clinical diagnosis and enriched the mutational spectrum of the ATP8B1 gene.
Humans ; Male ; Pedigree ; Cholestasis, Intrahepatic/diagnostic imaging* ; Adenosine Triphosphatases/genetics* ; Female ; Adult ; Exome Sequencing ; Mutation ; East Asian People

Objective:To investigate the effect of the embryo cryopreservation duration on pregnancy and obstetric outcome.Methods:A retrospective cohort study of 2 662 frozen-thawed embyro tranfer (FET) cycles was conducted in the Reproductive Medicine Center, Department of Obstetrics and Gynecology, Tianjin Medical University General Hospital from January 2016 to December 2020. According to embryo cryopreservation duration, the patients were divided into group A (≤1 year, n=2 115), group B (>1 years and ≤3 years, n=319), group C (>3 years and ≤6 years, n=174), and group D (>6 years, n=54). We used the propensity score matching (PSM) to match the baseline data of oocyte retrieval age of the other three groups according to group D at a ratio of 1∶3. Clinical and obstetric outcomes were compared among the four groups. Multiple logistic regression analysis was used to analyze the effect of oocyte retrieval age, embryo transfer age, the duration of embryo cryopreservation, endometrial preparation scheme, endometrial thickness, the number of transferred embryos and the number of high-quality embryos on pregnancy and live birth outcome. Results:1) Before PSM, there were significant differences in the maternal age at oocyte retrieval and embryo transfer and duration of embryo cryopreservation among the four groups(all P<0.001). 2) After PSM, the baseline characteristics of oocyte retrieval age reached a balance among the four groups. There were no statistical differences in the number of embryos transfer, the number of high-quality embryos, the transferred embryo stage, the endometrial regimen among the groups (all P>0.05). The clinical pregnancy rate [37.04% (20/54)] and the live birth rate [33.33% (18/54)] in group D were lower than those in group A [51.57% (82/159), 40.88% (65/159)], group B [50.00% (65/130), 40.77% (53/130)] and group C [49.59% (61/123), 39.02% (48/123)], but the difference was not statistically significant between the four groups ( P=0.310, P=0.781). There were no statistical differences among the four groups in the ratio of male to female newborns, gestational age, birth weight, preterm delivery rate, low birth weight rate, macrosomia rate, birth defects, and premature repture of membranes (all P>0.05). 3) Multiple logistic regression analysis showed that the number of high-quality embryos transferred affected the clinical pregnancy outcome (before PSM, OR=2.614, 95% CI: 2.168-3.151, P<0.001; after PSM, OR=1.984, 95% CI: 1.406-2.800, P<0.001) and live birth (before PSM, OR=2.708, 95% CI: 2.198-3.336, P<0.001; after PSM, OR=2.122, 95% CI: 1.474-3.053, P<0.001). The duration of embryo cryopreservation does not affect the clinical outcome and live birth (all P>0.05). Conclusion:The duration of embryo cryopreservation does not affect the clinical outcome and live birth, but large sample data are still needed to support this conclusion in the future.

Radiotherapy of the thoracic tumors may often involve incidental exposure of the heart to ionizing radiation,which leads to radiation-induced heart disease.Radiation-induced heart disease including pericarditis,cardiomyopathy,coronary heart disease,myocardial injury,valvular heart disease,cardiac conduction abnormalities,and so on.Myocardial injury is a more serious type,which may eventually lead to cardiovascular adverse outcomes such as heart failure,affecting the quality of life and clinical prognosis of cancer patients seriously.Therefore,this article will review the mechanism and imaging research progress of radioactive myocardial injury,so as to guide clinical comprehensive management.

Objective:To investigate the effect of the embryo cryopreservation duration on pregnancy and obstetric outcome.Methods:A retrospective cohort study of 2 662 frozen-thawed embyro tranfer (FET) cycles was conducted in the Reproductive Medicine Center, Department of Obstetrics and Gynecology, Tianjin Medical University General Hospital from January 2016 to December 2020. According to embryo cryopreservation duration, the patients were divided into group A (≤1 year, n=2 115), group B (>1 years and ≤3 years, n=319), group C (>3 years and ≤6 years, n=174), and group D (>6 years, n=54). We used the propensity score matching (PSM) to match the baseline data of oocyte retrieval age of the other three groups according to group D at a ratio of 1∶3. Clinical and obstetric outcomes were compared among the four groups. Multiple logistic regression analysis was used to analyze the effect of oocyte retrieval age, embryo transfer age, the duration of embryo cryopreservation, endometrial preparation scheme, endometrial thickness, the number of transferred embryos and the number of high-quality embryos on pregnancy and live birth outcome. Results:1) Before PSM, there were significant differences in the maternal age at oocyte retrieval and embryo transfer and duration of embryo cryopreservation among the four groups(all P<0.001). 2) After PSM, the baseline characteristics of oocyte retrieval age reached a balance among the four groups. There were no statistical differences in the number of embryos transfer, the number of high-quality embryos, the transferred embryo stage, the endometrial regimen among the groups (all P>0.05). The clinical pregnancy rate [37.04% (20/54)] and the live birth rate [33.33% (18/54)] in group D were lower than those in group A [51.57% (82/159), 40.88% (65/159)], group B [50.00% (65/130), 40.77% (53/130)] and group C [49.59% (61/123), 39.02% (48/123)], but the difference was not statistically significant between the four groups ( P=0.310, P=0.781). There were no statistical differences among the four groups in the ratio of male to female newborns, gestational age, birth weight, preterm delivery rate, low birth weight rate, macrosomia rate, birth defects, and premature repture of membranes (all P>0.05). 3) Multiple logistic regression analysis showed that the number of high-quality embryos transferred affected the clinical pregnancy outcome (before PSM, OR=2.614, 95% CI: 2.168-3.151, P<0.001; after PSM, OR=1.984, 95% CI: 1.406-2.800, P<0.001) and live birth (before PSM, OR=2.708, 95% CI: 2.198-3.336, P<0.001; after PSM, OR=2.122, 95% CI: 1.474-3.053, P<0.001). The duration of embryo cryopreservation does not affect the clinical outcome and live birth (all P>0.05). Conclusion:The duration of embryo cryopreservation does not affect the clinical outcome and live birth, but large sample data are still needed to support this conclusion in the future.

Objective:To explore the differences in the self-perceived burden of gastric cancer patients at different treatment time points and its relationship with family care and self-management efficacy, providing a reference for developing interventions to reduce self-perceived burden in gastric cancer patients.Methods:A convenience sampling method was used to select 151 gastric cancer patients who were hospitalized in the Department of Gastroenterology at Xinxiang Central Hospital from January 2022 to March 2024. Surveys were conducted at four time points: one day before surgery (T 1), after surgery and before the first chemotherapy (T 2), after the third chemotherapy (T 3), and after the sixth chemotherapy (T 4). The Self-Perceived Burden Scale, Family APGAR Index, and Chinese version of the Strategies Used by People to Promote Health were used. Repeated measures analysis of variance was applied to examine the trend of score changes at different time points, and multiple linear regression analysis was performed to explore the relationship between family care, self-management efficacy, and self-perceived burden at each time point. Results:The self-perceived burden scores of gastric cancer patients at the four time points were (31.11±7.86), (32.44±7.78), (33.44±7.45), and (33.17±7.06), respectively. Family care showed a negative impact on the self-perceived burden of patients at all four time points (standardized regression coefficients were -0.148, -0.733, -0.180, -0.218; P<0.05). Self-management efficacy also had a negative impact on the self-perceived burden at all four time points (standardized regression coefficients were -0.792, -0.209, -0.445, -0.402; P<0.05) . Conclusions:The self-perceived burden of gastric cancer patients increases gradually during treatment. Both family care and self-management efficacy negatively affect the self-perceived burden. Healthcare professionals should pay attention to the changes in self-perceived burden and its influencing factors during the treatment process, and develop targeted interventions to improve patients' self-perceived burden and quality of life.

Objective To study whether there are differences in immunological and hematological indexes in patients with extramed-ullary multiple myeloma(EMM).Methods The medical records of 150 newly diagnosed multiple myeloma(MM)patients admitted to Department of Hematology,the Second Hospital of Lanzhou University from January 2019 to January 2024 were retrospectively analyzed,to compare and analyze the differences in immunological and some hematological indexes between the EMM group(n=60)and the non-EMM group(n=90),and the two subgroups of the different risk stratification DS stages and Mayo myeloma risk stratification.Results The peripheral blood erythrocyte count,hemoglobin level,lactic acid dehydrogenase(LDH)level and interleukins-8(IL-8)levels of the patients in the EMM group were higher than those in the non-EMM group(P＜0.05),the interleukins-10(IL-10)and the pro-portion of CD4+T cells in the EMM group were lower than those in the non-EMM group(P＜0.05).Lymphocyte counts were signifi-cantly higher(P＜0.05)and the proportion of CD8+T cells was significantly lower(P＜0.05)in the EMM group of patients with stand-ard-risk MM.The proportion of peripheral blood CD8+T cells was significantly lower in the EMM group compared with the non-EMM group of patients with high-risk MM(P＜0.05).LDH levels were higher in the EMM group than that in the non-EMM group in both DS-Ⅰ and DS-Ⅱ MM patients(P＜0.05).Peripheral blood erythrocyte count,monocyte count,and hemoglobin level were higher in the EMM group than those in the non-EMM group in DS-Ⅲ MM patients(P＜0.05).Conclusion Immune abnormalities may be one of the factors contributing to the occurrence,development and poor prognosis of EMM.This study suggest that CD8+T cells,as immune effector cells,can be further studied in the occurrence and progression of MM to EMM,providing a new basis for clinical treatment.

The neonatal Fc receptor(FcRn)prolongs the half-life of immunoglobulin G(IgG)and promotes its recycling by binding to and making it an important receptor for maintaining serum IgG homeostasis.However,the abnormal accumulation of pathogenic IgG is closely related to the occurrence of various neuroimmune diseases.FcRn antagonists can significantly reduce the level of pathogenic IgG by blocking the binding of FcRn to IgG,thereby effectively alleviating the clinical symptoms of related diseases.As an emerging targeted therapeutic drug,FcRn antagonists have shown their potential in treating IgG-mediated neuroimmune diseases.This article summarizes the mechanism of action,types and clinical research progress of FcRn antagonists with the aim of providing new ideas for the precise treatment of IgG-mediated neuroimmune diseases.Future research should focus on the long-term safety of drugs,expansion of indications and individualized treatment strategies to further enhance their clinical application value.